Institution
Tehran University of Medical Sciences
Education•Tehran, Iran•
About: Tehran University of Medical Sciences is a education organization based out in Tehran, Iran. It is known for research contribution in the topics: Population & Cancer. The organization has 35661 authors who have published 57234 publications receiving 878523 citations. The organization is also known as: TUMS.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The effectiveness of the Iranian rural primary health-care system (the Behvarz system) in the management of diabetes and hypertension is examined, and whether the effects depend on the number ofhealth-care workers in the community is assessed.
209 citations
••
TL;DR: The results indicated that the annual levels of indoor and outdoor PM10 and PM2.5 were much higher than the guidelines issued by the World Health Organization (WHO) and the enrichment factors and diagnostic ratios indicated that combustion-related anthropogenic sources were the major sources of PAHs and trace metal(loid)s bound to PM.
209 citations
••
TL;DR: Amongst these useful herbs, some like Cinnamon, Silybum marianum, Garlic, Nigella, and Echium seem potential targets of future effective drugs for diseases in which free radical damage play a pathogenical role.
Abstract: Objective: This review focuses on the medicinal plants growing and having history of folk medicine in Iran and found effective as anti free radical damage in animal or human. Design: Embase, Scopus, Pubmed, Web of Science, Google Scholar, IranMedex, and SID databases were searched up to 2 February 2008. The search terms were antioxidant or "lipid peroxidation" and "plant, medicinal plant, herb, traditional, natural or herbal medicine" limited to Iran. Studies that assessed effects on cell lines or isolated organs, fetal toxicity, and reviews or letters were excluded. Antioxidative effect and lipid peroxidation inhibition were the key outcomes. Results: Forty-six animal studies on the efficacy of medicinal plants were reviewed. Lipid peroxidation was reduced in different clinical circumstances by Ferula szovitsiana, Nigella sativa, Rosa damascene petal, Phlomis anisodonta, Rose- mary, Zataria multiflora Boiss, Saffron, Amirkabiria odorastissima mozaffarian, Ficus carica Linn., Ziziphora clinopoi- des, Carica papaya, Chichorium intybus, Turmer, Eugenol, Curcumin, and Pistacia vera L. Human studies showed that Cinnamomum zeylanicum and Echium amoenum Fisch & C.A. Mey reduce lipid peroxidation and improve total antioxi- dant power in healthy subjects. Improvement of blood lipid profile was shown by Silybum marianum, garlic, and wheat germ. Conclusion: Amongst these useful herbs, some like Cinnamon, Silybum marianum, Garlic, Nigella, and Echium seem po- tential targets of future effective drugs for diseases in which free radical damage play a pathogenical role.
208 citations
••
TL;DR: Saffron at this dose was found to be effective similar to donepezil in the treatment of mild-to-moderate AD after 22 weeks, providing preliminary evidence of a possible therapeutic effect of saffron extract in the Treatment of patients with mild- to-moderate Alzheimer’s disease.
Abstract: Rationale There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer’s disease (AD). Objective The purpose of the present investigation was to assess the efficacy of C. sativus in the treatment of patients with mild-to-moderate AD. Methods Fifty-four Persian-speaking adults 55 years of age or older who were living in the community were eligible to participate in a 22-week, double-blind study of parallel groups of patients with AD. The main efficacy measures were the change in the Alzheimer’s Disease Assessment Scale—cognitive subscale and Clinical Dementia Rating Scale—Sums of Boxes scores compared with baseline. Adverse events (AEs) were systematically recorded. Participants were randomly assigned to receive a capsule saffron 30 mg/day (15 mg twice per day) or donepezil 10 mg/day (5 mg twice per day). Results Saffron at this dose was found to be effective similar to donepezil in the treatment of mild-to-moderate AD after 22 weeks. The frequency of AEs was similar between saffron extract and donepezil groups with the exception of vomiting, which occurred significantly more frequently in the donepezil group. Conclusion This phase II study provides preliminary evidence of a possible therapeutic effect of saffron extract in the treatment of patients with mild-to-moderate Alzheimer’s disease. This trial is registered with the Iranian Clinical Trials Registry (IRCT138711051556N1).
207 citations
••
University of New South Wales1, Veterans Health Administration2, University of Pennsylvania3, University of Zagreb4, Kurume University5, University of North Carolina at Chapel Hill6, University at Buffalo7, Tehran University of Medical Sciences8, University of Marburg9, University Medical Center Groningen10, Rabin Medical Center11, University Hospital of Bern12, Yonsei University13, Keio University14, Mayo Clinic15, Cairo University16, Icahn School of Medicine at Mount Sinai17, University of Utah18, Mercy Health19, Hokkaido University20, Medical University of Warsaw21, Akdeniz University22, Reims University23, Emory University24, Duke University25, Paracelsus Private Medical University of Salzburg26, Aristotle University of Thessaloniki27, Masaryk University28, Clínica Alemana29, Karadeniz Technical University30, University of Lübeck31, University of São Paulo32, University of California, Irvine33, Sheba Medical Center34, University of Parma35, University of Barcelona36, St. John's University37, Leicester Royal Infirmary38, United States Department of Veterans Affairs39, Stanford University40, University of California, Davis41
TL;DR: Recommendations from a subsequent Delphi consensus to broaden the generalizability of recommendations includes intravenous CD20 inhibitors as a first line therapy option for moderate to severe pemphigus.
Abstract: Background Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management. Objective We now present results from a subsequent Delphi consensus to broaden the generalizability of the recommendations. Methods A preliminary survey, based on the European Dermatology Forum and the European Academy of Dermatology and Venereology guidelines, was sent to a panel of international experts to determine the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in March 2016 during the annual American Academy of Dermatology conference. Following the meeting, a second survey was sent to more experts to achieve greater international consensus. Results The 39 experts participated in the first round of the Delphi survey, and 54 experts from 21 countries completed the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in Delphi II on the basis of Delphi results and meeting discussion. Limitations Each recommendation represents the majority opinion and therefore may not reflect all possible treatment options available. Conclusions We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first-line therapy option for moderate-to-severe pemphigus.
207 citations
Authors
Showing all 35946 results
Name | H-index | Papers | Citations |
---|---|---|---|
Graeme J. Hankey | 137 | 844 | 143373 |
Paul D.P. Pharoah | 130 | 794 | 71338 |
Jerome Ritz | 120 | 644 | 47987 |
Reza Malekzadeh | 118 | 900 | 139272 |
Robert N. Weinreb | 117 | 1124 | 59101 |
Javad Parvizi | 111 | 969 | 51075 |
Omid C. Farokhzad | 110 | 329 | 64226 |
Ali Mohammadi | 106 | 1149 | 54596 |
Alexander R. Vaccaro | 102 | 1179 | 39346 |
John R. Speakman | 95 | 667 | 34484 |
Philip J. Devereaux | 94 | 443 | 110428 |
Rafael Lozano | 94 | 265 | 126513 |
Mohammad Abdollahi | 90 | 1045 | 35531 |
Ingmar Skoog | 89 | 458 | 28998 |
Morteza Mahmoudi | 83 | 334 | 26229 |